2024 Annual Meeting | Industry Therapeutic Update from argenx: Our Evolving Understanding of CIDP: Pathophysiology, Current Unmet Treatment Needs, and the Rationale for Targeting FcRn

Date Tuesday 04/16/24

Time 06:00 PM - 08:00 PM MDT Add To Calendar

Location Hyatt Regency | Centennial F-G

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Richard Lewis, Christyn M. Edmundson, MD

Topic(s) General Neurology

Learning Objectives Join us for a discussion of the underlying immune mechanisms in chronic inflammatory demyelinating polyneuropathy (CIDP). Learn about ongoing efforts to inhibit IgG recycling for the potential treatment of adult patients with CIDP.

Provide an overview of CIDP, current understanding of pathophysiology, and unmet needs for treatments
Understand the rationale for targeting FcRn in CIDP

This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 07:00 PM MDT	Speaker	Industry Therapeutic Update from argenx: Our Evolving Understanding of CIDP: Pathophysiology, Current Unmet Treatment Needs, and the Rationale for Targeting FcRn

Faculty Disclosures
Richard Lewis	No disclosure on file
Christyn M. Edmundson, MD	Dr. Edmundson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion . Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Edmundson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam. Dr. Edmundson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB.